Geron Corporation Provides 2026 Financial Guidance
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: GlobeNewswire
2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, aiming to change lives by changing the course of blood cancer, today announced 2026 financial guidance. “Our priorities for 2026 are clear – driving RYTELO® commercial growth in the U.S., pursuing paths to bring RYTELO to LR-MDS markets outside the U.S., and advancing our Phase 3 IMpactMF trial,” said Harout Semerjian, President and Chief Executive Officer of Geron. “These priorities are supported by a focused commercial strategy, an expanding body of RYTELO scientific evidence and real-world experience, and a streamlined and energized Geron team. Together, these st
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B MilestonePR Newswire
- Is Geron (GERN) Using Its New ATM Program To Prioritize Flexibility Over Shareholder Dilution? [Yahoo! Finance]Yahoo! Finance
- Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments [Yahoo! Finance]Yahoo! Finance
- Geron Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
GERN
Earnings
- 2/25/26 - Miss
GERN
Sec Filings
- 3/3/26 - Form SCHEDULE
- 3/2/26 - Form S-3ASR
- 3/2/26 - Form 10-K
- GERN's page on the SEC website